D. E. Shaw & Co., Inc. 4 D Molecular Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 43,748 shares of FDMT stock, worth $900,333. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,748Holding current value
$900,333% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding FDMT
# of Institutions
157Shares Held
50.3MCall Options Held
718KPut Options Held
370K-
Vr Adviser, LLC New York, NY4.4MShares$90.6 Million12.03% of portfolio
-
Black Rock Inc. New York, NY4.28MShares$88.2 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.92MShares$80.7 Million3.74% of portfolio
-
Janus Henderson Group PLC London, X03.2MShares$65.8 Million0.06% of portfolio
-
Goldman Sachs Group Inc New York, NY3.06MShares$62.9 Million0.02% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $666M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...